Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Feb. 28, 2023

Variables used to determine the fair value of the options granted for the three months ended February 28, 2023 are as follows:


			Three months ended
			February 28,
			2023
Weighted average values:
Expected dividends			0%
Expected volatility			55.00%
Risk free interest rate			3.87%
Expected life			5 years

Stock Option Activity

Stock option activity for options with only service-based vesting conditions for the three months ended February 28, 2023, was as follows:


			Weighted		Weighted Average Remaining
			Average		Contractual		Aggregate
	Options		Exercise Price		Term (Years)		Intrinsic Value
Outstanding at November 30, 2022		329,314	$	8.36	4.68		$	37,250
Granted		113,000		4.68				—
Exercised		—		—				—
Expired/forfeited		—		—				—
Outstanding at February 28, 2023		442,314	$	7.42		4.54	$	20,750
Exercisable at February 28, 2023		320,671	$	7.48		4.46	$	20,750

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups outstanding and exercisable at February 28, 2023 and related price and contractual life information are as follows:


	Outstanding						Exercisable
			Weighted Average
			Remaining		Weighted				Weighted
Range of Exercise Prices	Outstanding		Contractual Life (Years)		Average Exercise Price		Outstanding		Average Exercise Price
$3.01 to $4.00		30,000		2.50	$	3.13		30,000	$	3.13
$4.01 to $5.00		113,000		4.85	$	4.68		50,000	$	4.62
$6.01 to $7.00		14,433		7.94	$	6.50		8,249	$	6.51
$7.01 to $8.00		194,781		4.71	$	7.63		180,829	$	7.60
$9.01 to $10.00		29,000		5.02	$	9.37		9,166	$	9.31
$12.01 to $13.00		16,653		7.48	$	12.54		12,799	$	12.58
$13.01 to $14.00		44,447		1.82	$	13.50		29,628	$	13.50
		442,314		4.54	$	7.42		320,671	$	7.48

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of February 28, 2023, and changes during the three months ended February 28, 2023, is presented below:


				Weighted Average
				Grant-Date
	Options			Fair Value
Non-vested at November 30, 2022		95,486		$	4.42
Granted		113,000			2.19
Vested		(86,843	)		3.17
Forfeited		—			—
Non-vested at February 28, 2023		121,643		$	3.24